---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-018608"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:37:22.071843+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics appoints Tim Ruan and Dr. Yi Zhang to board; Matthew McMurdo resigns

## Summary
- Appoints Tim Ruan as Class II director and Audit Committee member; qualifies as audit committee financial expert.
- Appoints Dr. Yi Zhang as Class II director and Nominating Committee member.
- Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement.
- Annual cash retainer for each new independent director is $30,000, payable quarterly, plus expense reimbursement.
- Both new directors are independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001493152-26-018608
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226018608/0001493152-26-018608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226018608/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-018608
- JSON: https://secwatch.observer/filing/0001493152-26-018608.json
- Plain text: https://secwatch.observer/filing/0001493152-26-018608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.